Literature DB >> 28823497

Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.

Charli Dominguez1, Justin M David1, Claudia Palena2.   

Abstract

Tumor growth and progression are the products of complex signaling networks between different cell types within the tumor and its surrounding stroma. In particular, established tumors are known to stimulate an inflammatory reaction via the secretion of cytokines, chemokines, and growth factors that favor the recruitment of a range of infiltrating immune cell populations into the tumor microenvironment. While potentially able to exert tumor control, this inflammatory reaction is typically seized upon by the tumor to promote its own growth and progression towards metastasis. This review focuses on recent advances in understanding how an established tumor can initiate an inflammatory response via the release of pro-inflammatory mediators, such as IL-6 and IL-8, and their roles in cancer metastasis. In particular, the role of the epithelial-mesenchymal transition (EMT), a phenotypic switch observed in carcinomas that promotes progression towards metastasis, is discussed here in relation to cancer inflammation. Published by Elsevier Ltd.

Entities:  

Keywords:  EMT; IL-6; IL-8; Inflammation

Mesh:

Substances:

Year:  2017        PMID: 28823497      PMCID: PMC5698091          DOI: 10.1016/j.semcancer.2017.08.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  129 in total

1.  Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Authors:  Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

2.  Interleukin-6 is an autocrine growth factor in human prostate cancer.

Authors:  D Giri; M Ozen; M Ittmann
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Authors:  Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

4.  Interleukin-8: A potent promoter of angiogenesis in gastric cancer.

Authors:  Jun Shi; Pin-Kang Wei
Journal:  Oncol Lett       Date:  2015-12-15       Impact factor: 2.967

Review 5.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

6.  IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.

Authors:  Vasilena Gocheva; Hao-Wei Wang; Bedrick B Gadea; Tanaya Shree; Karen E Hunter; Alfred L Garfall; Tara Berman; Johanna A Joyce
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

7.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

Authors:  J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

8.  Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.

Authors:  C Lütticken; U M Wegenka; J Yuan; J Buschmann; C Schindler; A Ziemiecki; A G Harpur; A F Wilks; K Yasukawa; T Taga
Journal:  Science       Date:  1994-01-07       Impact factor: 47.728

9.  Defensins. Natural peptide antibiotics of human neutrophils.

Authors:  T Ganz; M E Selsted; D Szklarek; S S Harwig; K Daher; D F Bainton; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

10.  Human breast cancer cells educate macrophages toward the M2 activation status.

Authors:  Sofia Sousa; Régis Brion; Minnamaija Lintunen; Pauliina Kronqvist; Jouko Sandholm; Jukka Mönkkönen; Pirkko-Liisa Kellokumpu-Lehtinen; Susanna Lauttia; Olli Tynninen; Heikki Joensuu; Dominique Heymann; Jorma A Määttä
Journal:  Breast Cancer Res       Date:  2015-08-05       Impact factor: 6.466

View more
  53 in total

1.  Streptococcus gordonii programs epithelial cells to resist ZEB2 induction by Porphyromonas gingivalis.

Authors:  Jun Ohshima; Qian Wang; Zackary R Fitzsimonds; Daniel P Miller; Maryta N Sztukowska; Young-Jung Jung; Mikako Hayashi; Marvin Whiteley; Richard J Lamont
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-10       Impact factor: 11.205

Review 2.  Inflammation and Cancer: Triggers, Mechanisms, and Consequences.

Authors:  Florian R Greten; Sergei I Grivennikov
Journal:  Immunity       Date:  2019-07-16       Impact factor: 31.745

3.  Effects of the media conditioned by various macrophage subtypes derived from THP-1 cells on tunneling nanotube formation in pancreatic cancer cells.

Authors:  Chia-Wei Lee; Chia-Chen Kuo; Chi-Jung Liang; Huei-Jyuan Pan; Chia-Ning Shen; Chau-Hwang Lee
Journal:  BMC Mol Cell Biol       Date:  2022-07-06

Review 4.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

5.  Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Authors:  Caroline Jochems; Sarah R Tritsch; Samuel Troy Pellom; Zhen Su; Patrick Soon-Shiong; Hing C Wong; James L Gulley; Jeffrey Schlom
Journal:  Oncotarget       Date:  2017-09-08

Review 6.  Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.

Authors:  Kristen Fousek; Lucas A Horn; Claudia Palena
Journal:  Pharmacol Ther       Date:  2020-09-24       Impact factor: 12.310

Review 7.  Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States.

Authors:  Laura Bornes; Guillaume Belthier; Jacco van Rheenen
Journal:  J Clin Med       Date:  2021-05-29       Impact factor: 4.241

Review 8.  The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition.

Authors:  Fernán Gómez-Valenzuela; Enrico Escobar; Ricardo Pérez-Tomás; Viviana P Montecinos
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 9.  miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation.

Authors:  Peng Jiao; Xing-Ping Wang; Zhuo-Ma Luoreng; Jian Yang; Li Jia; Yun Ma; Da-Wei Wei
Journal:  Int J Biol Sci       Date:  2021-06-04       Impact factor: 6.580

Review 10.  Cancer drug resistance induced by EMT: novel therapeutic strategies.

Authors:  Javier De Las Rivas; Anamaria Brozovic; Sivan Izraely; Alba Casas-Pais; Isaac P Witz; Angélica Figueroa
Journal:  Arch Toxicol       Date:  2021-05-18       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.